Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.50 |
| ▸ | C1S | P09871 | 3/20 | 0.50 |
| ▸ | TPMT | P51580 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 3/20 | 0.42 |
| ▸ | F10 | P00742 | 2/20 | 0.42 |
| ▸ | F12 | P00748 | 1/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.42 |
| ▸ | F3 | P13726 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL629198 | 0.97 | LMNA (0.58) | LMNAPRSS1PRSS3PRSS2C1S | |
| SCHEMBL17306879 | 0.84 | C1S (0.50) | LMNAPRSS1PRSS3PRSS2C1S | |
| SCHEMBL3335604 | 0.84 | LMNA (0.45) | LMNAPRSS1PRSS3PRSS2C1S | |
| SCHEMBL13948235 | 0.78 | PRSS1 (0.63) | LMNAPRSS1PRSS3PRSS2C1S | |
| SCHEMBL12857372 | 0.76 | MEN1 (0.51) | LMNAPRSS1PRSS3PRSS2F2 | |
| SCHEMBL2202463 | 0.75 | PARP1 (0.63) | LMNAPRSS1PRSS3PRSS2C1S | |
| Hydrochloric Acid SCHEMBL1436037 | 0.74 | PRSS1 (0.61) | LMNAPRSS1PRSS3PRSS2C1S | |
| SCHEMBL30936046 | 0.74 | HCAR2 (0.55) | LMNAPRSS1PRSS3PRSS2C1S | |
| SCHEMBL17191008 | 0.72 | TPMT (0.46) | LMNATPMTTSHRHTR3EHTR3B | |
| SCHEMBL1219593 | 0.72 | LMNA (0.95) | LMNAPRSS1PRSS3PRSS2C1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380538-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | AHAMMUNE BIOSCIENCES PRIVATE LTD (IN) | 2021-12-09 | — | — | US | disclosed |
| US-9508939-B2 | Compound and organic electroluminescent element produced using same | IDEMITSU KOSAN CO., LTD. (JP) | 2016-11-29 | — | — | US | disclosed |
| US-9508939-B2 | Compound and organic electroluminescent element produced using same | IDEMITSU KOSAN CO., LTD. (JP) | 2016-11-29 | — | — | US | disclosed |
| US-20160172604-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160172604-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| EP-1534680-B1 | PRENYLATION INHIBITORS AND METHODS OF THEIR SYNTHESIS AND USE | PHARMACO INVESTMENTS INC (US) | 2012-02-22 | — | — | EP | disclosed |
| CN-1713907-B | N-substituted pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors | HOFFMANN LA ROCHE | 2010-05-26 | — | — | CN | disclosed |
| US-20080119524-A1 | PRENYLATION INHIBITORS CONTAINING DIMETHYLCYCLOBUTANE AND METHODS OF THEIR SYNTHESIS AND USE | PHARMACEUTICAL PRODUCT DEVELOPMENT, INC. | 2008-05-22 | — | — | US | disclosed |
| US-7166619-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY , INC. (US) | 2007-01-23 | — | — | US | disclosed |
| CN-1713907-A | N-substituted pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors | HOFFMANN LA ROCHE (CH) | 2005-12-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380538-A1 | NOVEL IMIDAZOLE COMPOUNDS, PROCESS FOR THE SYNTHESIS AND USES THEREOF | IDO1, IDO2, NFATC1 | LMNA 4399/4885PRSS1 2691/4885PRSS3 3751/4885 |
| US-20160172604-A1 | NOVEL COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT PRODUCED USING SAME | L1CAM, LEF1, EML4 | LMNA 319/4885PRSS1 3377/4885PRSS3 4148/4885 |
| US-20080119524-A1 | PRENYLATION INHIBITORS CONTAINING DIMETHYLCYCLOBUTANE AND METHODS OF THEIR SYNTHESIS AND USE | RCE1, GGPS1, FNTA | LMNA 723/4885PRSS1 1927/4885PRSS3 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.